logo-loader
HealthPharma & Biotech
ReNeuron Group PLC

ReNeuron primed for further progress

ReNeuron Group PLC is at the forefront of stem cell science

1555510853_A-Cell.jpg
The next data dump will be on April 26
  • Developer of stem cell technologies

  • Has two clinical stage technologies

  • Stroke treatment in Phase IIb trials

  • Recently inked a Chinese licensing deal

 

What ReNeuron Does

It has unique stem cell technologies that can be administered “off-the-shelf”. Its lead candidate has been developed to treat people disabled by a stroke.

The company has announced positive Phase II data from patients treated with its neural stem cells, with a Phase IIb trial imminent.

Its human retinal progenitor cells (hRPC), meanwhile, have scored some early success. A Phase I/II assessment of a very small group of sufferers of a blindness-causing disease called retinitis pigmentosa saw a significant improvement in vision after treatment.

"We remain extremely encouraged by the positive efficacy data we have seen thus far,” said chief executive Olav Hellebø recently. “These results have already attracted considerable interest, particularly from those in the ophthalmology field.”

Inflexion Points

PISCES III trial: This is the Phase IIb study in the US for people suffering from a stroke. This particular trial is placebo-controlled, which means half the patients will receive a substance with no therapeutic value to provide a control group. A total of 110 people are being recruited at 40 site across the States.

Additional data from the ongoing Phase I/II trial of the retinal stem cell treatment are being presented at gene and cell therapy conference on April 26.

A big long-term value kicker was announced earlier this month (April) when the company struck a licensing deal with Chinese pharma Fosun worth up to £80mln over the next few years.

Deals for its two clinical-stage treatments would provide third-party validation for the technology, but could conceivably be worth much more than the Fosun tie-up.

Blue Sky

The share price has rocketed from 50p to 250p on the back of the recent news flow. But even so, analysts believe there is more ‘upside’. However, Edison Research believes the company is worth 630p. The broker Stifel has a price target of 690p. “The business remains significantly undervalued, and we look forward to further clinical data on the retinal programme at the end of April, and potential further licensing activity, as near-term catalysts to build on recent momentum,” it said in a note earlier this month.

Quick facts: ReNeuron Group PLC

Price: £2.02

Market: LSE
Market Cap: £64.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ReNeuron signs retinal stem cell exclusivity agreement

ReNeuron Group Plc (LON:RENE) has inked a deal worth up to US$5mln ahead of potentially licensing out its ground-breaking its hRPC retinal stem cell technology and therapeutic programmes. CFO Michael Hunt says they're hoping the exclusivity agreement with an unnamed US-based speciality...

on 11/7/18

2 min read